These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 2507341

  • 1. Prevention or moderation of some ultrastructural changes in the RPE and retina of galactosemic rats by aldose reductase inhibition.
    Vinores SA, Campochiaro PA.
    Exp Eye Res; 1989 Sep; 49(3):495-510. PubMed ID: 2507341
    [Abstract] [Full Text] [Related]

  • 2. Ultrastructural localization of blood-retinal barrier breakdown in diabetic and galactosemic rats.
    Vinores SA, McGehee R, Lee A, Gadegbeku C, Campochiaro PA.
    J Histochem Cytochem; 1990 Sep; 38(9):1341-52. PubMed ID: 2117624
    [Abstract] [Full Text] [Related]

  • 3. Permeability changes in blood-retinal barrier of galactosemic rats are prevented by aldose reductase inhibitors.
    Lightman S, Rechthand E, Terubayashi H, Palestine A, Rapoport S, Kador P.
    Diabetes; 1987 Nov; 36(11):1271-5. PubMed ID: 3117606
    [Abstract] [Full Text] [Related]

  • 4. Increases in collagen type IV and laminin in galactose-induced retinal capillary basement membrane thickening--prevention by an aldose reductase inhibitor.
    Das A, Frank RN, Zhang NL, Samadani E.
    Exp Eye Res; 1990 Mar; 50(3):269-80. PubMed ID: 2108050
    [Abstract] [Full Text] [Related]

  • 5. The polyol pathway in retinal microangiopathy.
    Robison WG, Kinoshita JH, Kador PF.
    Drugs; 1986 Mar; 32 Suppl 2():19-22. PubMed ID: 3098542
    [Abstract] [Full Text] [Related]

  • 6. The effects of aldose reductase inhibition on nerve sorbitol and myoinositol concentrations in diabetic and galactosemic rats.
    Yue DK, Hanwell MA, Satchell PM, Handelsman DJ, Turtle JR.
    Metabolism; 1984 Dec; 33(12):1119-22. PubMed ID: 6438438
    [Abstract] [Full Text] [Related]

  • 7. Galactose-induced retinal microangiopathy in rats.
    Kern TS, Engerman RL.
    Invest Ophthalmol Vis Sci; 1995 Feb; 36(2):490-6. PubMed ID: 7843917
    [Abstract] [Full Text] [Related]

  • 8. Retinal polyol and myo-inositol in galactosemic dogs given an aldose-reductase inhibitor.
    Kern TS, Engerman RL.
    Invest Ophthalmol Vis Sci; 1991 Dec; 32(13):3175-7. PubMed ID: 1748548
    [Abstract] [Full Text] [Related]

  • 9. Galactose cataract prevention with sorbinil, an aldose reductase inhibitor: a light microscopic study.
    Datiles M, Fukui H, Kuwabara T, Kinoshita JH.
    Invest Ophthalmol Vis Sci; 1982 Feb; 22(2):174-9. PubMed ID: 6799419
    [Abstract] [Full Text] [Related]

  • 10. Treatment with aldose reductase inhibitor or with myo-inositol arrests deterioration of the electroretinogram of diabetic rats.
    MacGregor LC, Matschinsky FM.
    J Clin Invest; 1985 Aug; 76(2):887-9. PubMed ID: 3928685
    [Abstract] [Full Text] [Related]

  • 11. Effects of an aldose reductase inhibitor, SNK-860, on the histopathological changes of retinal tissues in a streptozotocin-induced diabetic rat model.
    Akita M, Mizuno K, Matsubara A, Nakano K, Kurono M.
    Acta Med Okayama; 1993 Oct; 47(5):299-304. PubMed ID: 8273453
    [Abstract] [Full Text] [Related]

  • 12. Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor.
    Robison WG, Kador PF, Kinoshita JH.
    Science; 1983 Sep 16; 221(4616):1177-9. PubMed ID: 6612330
    [Abstract] [Full Text] [Related]

  • 13. Aldose reductase activity and basement membrane thickening.
    Frank RN.
    Metabolism; 1986 Apr 16; 35(4 Suppl 1):35-40. PubMed ID: 3083207
    [Abstract] [Full Text] [Related]

  • 14. Discordant effects of the aldose reductase inhibitor, sorbinil, on vascular structure and function in chronically diabetic and galactosemic rats.
    Tilton RG, Pugliese G, LaRose LS, Faller AM, Chang K, Province MA, Williamson JR.
    J Diabet Complications; 1991 Apr 16; 5(4):230-7. PubMed ID: 1779018
    [Abstract] [Full Text] [Related]

  • 15. Electron microscopic immunocytochemical evidence for the mechanism of blood-retinal barrier breakdown in galactosemic rats and its association with aldose reductase expression and inhibition.
    Vinores SA, Van Niel E, Swerdloff JL, Campochiaro PA.
    Exp Eye Res; 1993 Dec 16; 57(6):723-35. PubMed ID: 8150024
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Capillary basement membrane in retina, kidney, and muscle of diabetic dogs and galactosemic dogs and its response to 5 years aldose reductase inhibition.
    Engerman RL, Kern TS, Garment MB.
    J Diabetes Complications; 1993 Dec 16; 7(4):241-5. PubMed ID: 8219367
    [Abstract] [Full Text] [Related]

  • 18. Effects of aldose reductase inhibition on the retina and health indices of streptozotocin-diabetic rats.
    Kozak WM, Marker NA, Elmer KK.
    Doc Ophthalmol; 1986 Dec 16; 64(4):355-77. PubMed ID: 2958262
    [Abstract] [Full Text] [Related]

  • 19. Aldose reductase inhibition fails to prevent retinopathy in diabetic and galactosemic dogs.
    Engerman RL, Kern TS.
    Diabetes; 1993 Jun 16; 42(6):820-5. PubMed ID: 8495805
    [Abstract] [Full Text] [Related]

  • 20. The effects of sorbinil, an aldose reductase inhibitor, on the corneal endothelium in galactosemic dogs.
    Datiles MB, Kador PF, Kashima K, Kinoshita JH, Sinha A.
    Invest Ophthalmol Vis Sci; 1990 Nov 16; 31(11):2201-4. PubMed ID: 2122961
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.